Skip to main content

Table 3 Rate and risk of the secondary endpoints in the three study groups after propensity score matching

From: Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction

 

Non-DM pts (n = 1030)

DM pts treated with GLP-1 RA/SGLT-2i (n = 1030)

DM pts not treated with GLP-1 RA/SGLT-2i (n = 1030)

P value

In-hospital mortality

 n (%)

27 (3%)

35 (3%)

40 (4%)

0.10 (for trend)

 OR (95% CI)

Reference

1.31 (0.78–2.18)

1.50 (0.91–2.46)

0.11 (for trend)

 OR (95% CI)*

–

Reference

1.08 (0.67–1.76)

0.24

Acute heart failure

 n (%)

108 (10%)

137 (13%)

169 (16%)

 < .0001 (for trend)

 OR (95% CI)

Reference

1.31 (1.01–1.71)

1.68 (1.29–2.17)

 < .0001 (for trend)

 OR (95% CI)a

–

Reference

1.31 (1.02–1.70)

0.004

Severe AKI (RRT)

 n (%)

13 (1%)

3 (0.3%)

17 (2%)

0.39 (for trend)

 OR (95% CI)

Reference

0.23 (0.07–0.81)

1.31 (0.63–2.72)

0.039 (for trend)

 OR (95% CI)a

–

Reference

4.88 (1.36–17.6)

0.02

  1. aAdjusted for anti-hyperglycemic therapy before hospitalization
  2. AKI Acute kidney injury, CI confidence interval, DM diabetes mellitus, OR odds ratio, RRT renal replacement therapy